News | December 20, 2021
Moderna says Covid-19 booster dose works against Omicron in lab study
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
Expertise in exosomes isolation and characterization will drive innovation in this field
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Subscribe To Our Newsletter & Stay Updated
